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Blood Transfusion*
George Dangas, MD,y Jaya Chandrasekhar, MBBSzI n transfusing patients with red blood cells,physicians and surgeons aim to enhance thecirculatory oxygen-carrying capacity that has
been compromised due to blood loss or a hemato-
logical disorder. In general, bleeding and transfu-
sion strongly correlate with adverse outcomes in
patients undergoing percutaneous coronary inter-
vention (PCI) (1,2). Understandably, these negative
reports have culminated in a higher threshold among
physicians to prescribe blood transfusion (3). None-
theless, there is considerable variation in transfusion
practices in U.S. hospitals, and current transfusion
guidelines reﬂect the uncertainty stemming from
the available evidence (3,4). The ﬁeld of interven-
tional cardiology is no exception to this, and the ideal
place of blood transfusion around the time of PCI is
unclear.SEE PAGE 436In this issue of JACC: Cardiovascular Interventions,
Kwok et al. (5) describe a meta-analysis of 19 studies
and 54,000 transfusion events in 2,258,711 patients
undergoing PCI, for clinical outcomes of major
adverse cardiac events and death at any time point.
Follow-up varied from in-hospital to 5 years. In the
absence of patient-level data, the authors report the
crude mortality at any time point in transfused
patients (based on available data from 8 of 19 studies)
at 12.6% versus 1.2% in nontransfused patients.
Likewise, the crude major adverse cardiac events rate
(based on available data from 5 of 19 studies) was
17.4% versus 3.1% in nontransfused patients. The*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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this paper to disclose.primary limitation with a meta-analysis on this sub-
ject is the inherent difﬁculty in separating mortality
resulting from bleeding, particularly in the very
early time frame of the index hospitalization. In an
attempt to address this issue, the authors provide
mortality outcomes adjusted for baseline hematocrit
(2 studies), baseline anemia (5 studies), and bleeding
based on a hematocrit drop (3 studies). The adverse
inﬂuence of transfusion on mortality remained inde-
pendently of these factors. Furthermore, the authors
also show that the mortality risk increased with the
number of units transfused, particularly for patients
receiving more than 3 units. Correspondingly, they
emphasize the importance of bleeding avoidance
strategies to preclude the need for blood transfusion
in the ﬁrst place.
However, are these statistical adjustments able to
adequately account for the propensity of physicians
to transfuse patients for acute or life-threatening
reasons? Is any statistical adjustment adequate to
demonstrate that transfused patients would in fact
have survived bleeding in the absence of transfusion
had they been managed with a more conservative
approach instead? The answer to both of these ques-
tions is “no” because these subjects are deeply clin-
ical and not purely statistical, often related to
variables that are not collected and analyzed in
research databases. The same holds true for the de-
cision of how many units to transfuse and how this
may be reﬂected as a gradient of risk and beneﬁt;
this variable was not comprehensively analyzed by
Kwok et al. (5) (as only 2 of 19 studies provide rele-
vant data). Additionally, the potential outcome dif-
ferences with whole blood versus packed red cell
transfusion versus transfusion of other blood sub-
stitutes warrant future investigation.
The risks of transfusion are related not only to
transmission of infections but also to transfusion
reactions, acute lung injury, circulatory overload, and
immunosuppression (6). The mechanism by which
TABLE 1 Patient Classiﬁcation Based on Circulatory Oxygen Delivery
Supply-Demand Mismatch
Supply-Demand
Mismatch Clinical Features
Transfusion
Indication Risk-Beneﬁt Ratio
Hyperacute Symptomatic, acute blood
loss, hemodynamically
unstable
Life threatening Risk of death > risk
of transfusion
Acute/subacute Recent slow blood loss or
symptomatic chronic
anemia (fatigue),
hemodynamically
stable
Intermediate Risk of clinical
deterioration y risk
of transfusion
Chronic Asymptomatic
chronic anemia
Elective Risk of clinical
deterioration < risk
of transfusion
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448transfusion may cause cardiovascular adverse events
is thought to be by reducing circulating levels of
nitric oxide and subsequently reduced circulatory
oxygen-carrying capacity, development of hyper-
dynamic circulatory physiology (and high output
heart failure in certain instances), an increase in
platelet reactivity and proportion of procoagulant
proteins, impaired small-vessel vasodilation, and
deformation of red cell shapes in storage resulting in
small-vessel plugging and ischemia (7).
In the study by Sherwood et al. (3), patients
transfused for hemoglobin #10 g/dl and bleeding
derived the greatest beneﬁt, whereas transfusion for
hemoglobin >10 g/dl was associated with adverse
outcomes irrespective of bleeding. Intuitively, pa-
tients who beneﬁt the most from blood transfusion
also comprise the sickest cohort with greaterFIGURE 1 Potential Trial Proﬁlecomorbidities and hemodynamic compromise in the
context of either acute blood loss or chronic ane-
mia. No single laboratory value (hematocrit or
hemoglobin included) can therefore be an abso-
lute “automatic” trigger for transfusion. Thus, the
pertinent question remains: Who is eligible to
receive a transfusion and how could a prospec-
tive clinical trial shed light on this complex
subject? Earlier studies have produced inconclusive
results (8,9).
Although Kwok et al. (5) recommend that physi-
cians should “minimize” transfusions, there are
currently no well-established ways to do so in the
acute in-hospital scenario. To better understand the
clinical decision-making process of whom to trans-
fuse, one may derive a patient classiﬁcation based on
the severity of circulatory oxygen delivery supply-
demand mismatch (Table 1). Of these, the intermedi-
ate group deserves closer attention: given that these
are hemodynamically stable patients, could alterna-
tives to transfusion (e.g., synthetic red cell sub-
stitutes, iron supplementation, erythropoietin) be
suitable options?
Data on red cell substitutes such as recombinant
hemoglobin, hemoglobin-based oxygen carriers, and
ﬂuorocarbon-based oxygen carriers is evolving, but
currently, these oxygen-carrying compounds are not
available for clinical use. In contrast, physicians have
long-term experience with oral iron supplementation,
which has proved to be safe, inexpensive, and effec-
tive. The gastrointestinal side effects of oral iron and
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449the ensuing issues with adherence may be avoided
with the use of parenteral iron or erythropoietin.
Additionally, the question of whether transfusion
is truly harmful can only be answered in the context
of a well-designed, randomized, controlled trial. Such
a trial would ﬁrst of all exclude patients who would
not survive without immediate transfusion and then
randomize the remaining patients with a comparable
level of anemia to receive a transfusion-based strat-
egy or not. The patients not receiving transfusion
could be further randomized to receive alternative
forms of therapy (Figure 1). The main study outcomes
of interest are mortality and bailout transfusion.
Although the meta-analysis by Kwok et al. (5)
serves as a stark reminder of the potential adverse
prognostic effects of transfusion, the wait continuesfor the ideal prospective, randomized trial that will
deﬁnitively alter our practice and allay our fears.
Until then, clinicians should continue to adopt best
practice with prudent use of transfusion based on the
severity of patient presentation. More importantly, it
is paramount that a bleeding avoidance strategy (with
upfront risk stratiﬁcation as well as active procedural
measures) be meticulously adopted in all invasive
procedures to prevent signiﬁcant acute anemia. This
may be the single most important take-home message
from the present comment!
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